Images List Premium Download Classic

Histocompatibility

Histocompatibility-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Histone anti-cancer vaccines
Deutsches Krebsforschungszentrum
June 07, 2018 - N°20180155403

The present invention pertains to novel immunogenic peptide sequences that can be used as vaccines in the treatment of cancer diseases such as brain cancers and specifically glioma. The cancer vaccines of the invention are designed based on the k27m mutated variant of the human histone 3.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
May 24, 2018 - N°20180141993

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Humanized t cell mediated immune responses in non-human animals
Regeneron Pharmaceuticals, Inc.
May 24, 2018 - N°20180139940

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized t cell co-receptor (e.g., humanized cd4 and/or cd8 (e.g., cd8α and/or cd8β)), a human or humanized t cell receptor (tcr) comprising a variable domain encoded by at least one human tcr variable region ...
Histocompatibility Patent Pack
Download + patent application PDFs
Histocompatibility Patent Applications
Download + Histocompatibility-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histocompatibility-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other ...
Immatics Biotechnology Gmbh
May 10, 2018 - N°20180127473

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and ...
Immatics Biotechnologies Gmbh
May 03, 2018 - N°20180117085

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Genetically modified major histocompatibility complex mice
Regeneron Pharmaceuticals, Inc.
May 03, 2018 - N°20180116190

The invention provides genetically modified non-human animals that express chimeric human/non-human mhc i and mhc ii polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.
Histocompatibility Patent Pack
Download + patent application PDFs
Histocompatibility Patent Applications
Download + Histocompatibility-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histocompatibility-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
April 05, 2018 - N°20180094043

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Delivery of rna to trigger multiple immune pathways
Glaxosmithkline Biologicals, Sa
March 29, 2018 - N°20180085388

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
Curevac Ag
March 22, 2018 - N°20180078629

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (mhc) class i restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination.
Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors ...
Helmholtz Zentrum MÜnchen-deutsches Forschungszentrum FÜr Gesundheit Und
March 15, 2018 - N°20180073013

The present invention relates to the field of immunotherapy, in particular, to adoptive t cell therapy, t cell receptor (tcr) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the tcr alpha chain construct (tra) and tcr beta chain construct (trb) of a tcr construct specific for an epitope from an antigen presented on ...
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other ...
Immatics Biotechnologies Gmbh
March 08, 2018 - N°20180066032

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell ...
Immatics Biotechnologies Gmbh
March 08, 2018 - N°20180064796

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma ...
Immatics Biotechnologies Gmbh
March 01, 2018 - N°20180055883

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Histocompatibility Patent Pack
Download + patent application PDFs
Histocompatibility Patent Applications
Download + Histocompatibility-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Histocompatibility-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Delivery of rna to different cell types
Glaxosmithkline Biologicals, Sa
February 22, 2018 - N°20180050059

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037629

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 08, 2018 - N°20180037628

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Compositions and methods for enhancing an immune response
The Johns Hopkins University
February 08, 2018 - N°20180037621

The disclosure features compounds comprising an antigen portion, a soluble major histocompatibility complex (mhc) molecule portion (e.g., all or an antigen-binding portion of a soluble mhc class i molecule), and a dynamic anchor portion (e.g., an agent, such as annexin v, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e....
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
February 01, 2018 - N°20180030113

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Novel minor histocompatibility antigens and uses thereof
Rsem, Limited Partnership
February 01, 2018 - N°20180030112

Novel minor histocompatibility antigens (mihas) are described. These novel mihas were selected based on two features: (i) they are encoded by loci with a minor allele frequency (maf) of at least 0.05; and (ii) they have adequate tissue distribution.
Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer ...
Immatics Biotechnologies Gmbh
November 30, 2017 - N°20170342125

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Molecular constructs and uses thereof
The University Of Notre Dame Du Lac
November 23, 2017 - N°20170333524

Molecular constructs and dual recognition constructs having a sequence encoding a tcr affinity weakening motif, and dna and rna sequences corresponding thereto, are presented. Modified t-cells and other cells transformed with the molecular contracts express a modified tcr that imparts a reduction, in non-specific binding, an enhancement of binding specificity and an enhancement of binding affinity for a target antigen, ...
Loading